tetano
Editor, Senior Moderator
Med Clin (Engl Ed)
. 2022 Dec 23;159(12):569-574.
doi: 10.1016/j.medcle.2022.02.029. Epub 2022 Dec 15.
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease
Haitham M H Qutob[SUP] 1 2 [/SUP], Ramadan A Saad[SUP] 2 3 [/SUP], Hamza Bali[SUP] 4 [/SUP], Abdulaziz Osailan[SUP] 4 [/SUP], Jumana Jaber[SUP] 4 [/SUP], Emad Alzahrani[SUP] 4 [/SUP], Jamilah Alyami[SUP] 4 [/SUP], Hani Elsayed[SUP] 2 5 [/SUP], Raed Alserihi[SUP] 6 7 [/SUP], Osama A Shaikhomar[SUP] 8 [/SUP]
Affiliations
Abstract
in English, Spanish
Background and aim: The most effective way to control severity and mortality rate of the novel coronavirus disease (COVID-19) is through sensitive diagnostic approaches and an appropriate treatment protocol. We aimed to identify the effect of adding corticosteroid and Tocilizumab to a standard treatment protocol in treating COVID-19 patients with chronic disease through hematological and lab biomarkers.
Materials and methods: This study was performed retrospectively on 68 COVID-19 patients with chronic disease who were treated by different therapeutic protocols. The patients were categorized into four groups: control group represented the patients' lab results at admission before treatment protocols were applied; group 1 included patients treated with anticoagulants, Hydroxychloroquine, and antibiotics; group 2 comprised patients treated with Dexamethasone; and group 3 included patients treated with Dexamethasone and Tocilizumab.
Results: The WBC and neutrophil counts were increased significantly in group 3 upon the treatment when they were compared with patients in group 1 (p = 0.004 and p = 0.001, respectively). The comparison of C-reactive Protein (CRP) level at admission was higher in group 3 than in group 1 with p = 0.030. After 10 days of treatment, CRP level was decreased in all groups, but in group 3 it was statistically significant (p = 0.002).
Conclusion: The study paves the way into the effectiveness of combining Dexamethasone with Tocilizumab in treatment COVID-19 patients with chronic diseases.
Keywords: ARDS, severe acute respiratory distress syndrome; CBC, complete blood count; COVID-19; COVID-19, coronavirus disease 2019; CRP; CRP, C-reactive protein; Dexamethasone; Lymphocytes; Neutrophils; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Tocilizumab; WBCs.
. 2022 Dec 23;159(12):569-574.
doi: 10.1016/j.medcle.2022.02.029. Epub 2022 Dec 15.
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease
Haitham M H Qutob[SUP] 1 2 [/SUP], Ramadan A Saad[SUP] 2 3 [/SUP], Hamza Bali[SUP] 4 [/SUP], Abdulaziz Osailan[SUP] 4 [/SUP], Jumana Jaber[SUP] 4 [/SUP], Emad Alzahrani[SUP] 4 [/SUP], Jamilah Alyami[SUP] 4 [/SUP], Hani Elsayed[SUP] 2 5 [/SUP], Raed Alserihi[SUP] 6 7 [/SUP], Osama A Shaikhomar[SUP] 8 [/SUP]
Affiliations
- PMID: 36536624
- PMCID: PMC9752094
- DOI: 10.1016/j.medcle.2022.02.029
Abstract
in English, Spanish
Background and aim: The most effective way to control severity and mortality rate of the novel coronavirus disease (COVID-19) is through sensitive diagnostic approaches and an appropriate treatment protocol. We aimed to identify the effect of adding corticosteroid and Tocilizumab to a standard treatment protocol in treating COVID-19 patients with chronic disease through hematological and lab biomarkers.
Materials and methods: This study was performed retrospectively on 68 COVID-19 patients with chronic disease who were treated by different therapeutic protocols. The patients were categorized into four groups: control group represented the patients' lab results at admission before treatment protocols were applied; group 1 included patients treated with anticoagulants, Hydroxychloroquine, and antibiotics; group 2 comprised patients treated with Dexamethasone; and group 3 included patients treated with Dexamethasone and Tocilizumab.
Results: The WBC and neutrophil counts were increased significantly in group 3 upon the treatment when they were compared with patients in group 1 (p = 0.004 and p = 0.001, respectively). The comparison of C-reactive Protein (CRP) level at admission was higher in group 3 than in group 1 with p = 0.030. After 10 days of treatment, CRP level was decreased in all groups, but in group 3 it was statistically significant (p = 0.002).
Conclusion: The study paves the way into the effectiveness of combining Dexamethasone with Tocilizumab in treatment COVID-19 patients with chronic diseases.
Keywords: ARDS, severe acute respiratory distress syndrome; CBC, complete blood count; COVID-19; COVID-19, coronavirus disease 2019; CRP; CRP, C-reactive protein; Dexamethasone; Lymphocytes; Neutrophils; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Tocilizumab; WBCs.